Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 549 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Median Survival Times for Two Forms of Advanced Breast Cancer Have... November 9, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... November 17, 2023 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 How to Find the Right Hospice Care Program for You or... August 10, 2023 Load more HOT NEWS Man Who Lost Wife to Breast Cancer Wants to Donate Her... A Summer Poem A New FDA Approval Furthers the Role of Genomics in Cancer... Foodie Friday: Watermelon Fruit Pizza
